Ernexa Therapeutics Inc (ERNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Sales | 0 | 1 | 487 | 47 | 47 |
| Cost of Goods | N/A | 0 | -60 | 95 | 61 |
| Gross Profit | N/A | 1 | 547 | -48 | -14 |
| Operating Expenses | 2,730 | 2,698 | 2,746 | 4,978 | 5,834 |
| Operating Income | -2,730 | -2,697 | -2,259 | -4,931 | -5,787 |
| Other Income | -5,464 | -3,051 | -24,333 | -595 | -856 |
| Pre-tax Income | -8,194 | -5,748 | -26,592 | -5,526 | -6,643 |
| Income Tax | 8 | 11 | 12 | 3 | 4 |
| Net Income Continuous | -8,202 | -5,759 | -26,604 | -5,529 | -6,647 |
| Net Income | $-8,202 | $-5,759 | $-26,604 | $-5,529 | $-6,647 |
| EPS Basic Total Ops | -57.76 | 1,463.02 | -1,842.50 | -383.50 | -461.02 |
| EPS Basic Continuous Ops | -57.76 | 1,462.19 | -1,842.38 | -382.89 | -460.51 |
| EPS Diluted Total Ops | -57.76 | 1,463.02 | -1,842.50 | -383.50 | -461.02 |
| EPS Diluted Continuous Ops | -57.76 | 1,462.19 | -1,842.38 | -382.89 | -460.51 |
| EPS Diluted Before Non-Recurring Items | -56.22 | N/A | -1,844.08 | N/A | N/A |
| EBITDA(a) | $-2,661 | $482 | $-579 | $-3,879 | $-4,801 |